Browsing Category
Pharma Industry News
4731 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Abbott expands diagnostics empire with $23bn takeover of cancer-test leader Exact Sciences
Find out how Abbott’s $23B acquisition of Exact Sciences could reshape cancer diagnostics and redefine growth in oncology screening.
Innovent Biologics hits 20% weight loss in Phase 3: Will mazdutide become China’s Ozempic?
Mazdutide 9 mg achieves 20.08% weight loss in pivotal Chinese Phase 3 study. Learn what this means for Innovent Biologics’ NDA plans and obesity treatment.
Hanmi Pharmaceutical to acquire Aptose Biosciences in C$2.41-per-share deal with 28% premium
Find out how Hanmi Pharmaceutical’s acquisition of Aptose Biosciences is reshaping the AML treatment landscape today!
Agios shakes up sickle cell therapy landscape with mixed but promising RISE UP phase 3 data for mitapivat
Find out how Agios’ mixed but promising RISE UP phase 3 data for mitapivat could reshape sickle cell treatment and influence regulatory decisions.
Alkermes raises Avadel bid to $2.37bn with enhanced CVR terms tied to LUMRYZ FDA milestone
Alkermes raises Avadel bid to $2.37B with improved CVR linked to FDA approval for LUMRYZ in idiopathic hypersomnia. Read the full transaction breakdown.
Avidity Biosciences (Nasdaq: RNA) opens access to del-zota in DMD44 as BLA filing nears
Avidity Biosciences launches U.S. access program for del-zota in DMD exon 44 patients. See how this ties into FDA submission plans and the Novartis acquisition.
CD388 in focus as Merck announces $9.2bn deal for Cidara Therapeutics (NASDAQ: CDTX)
Merck is acquiring Cidara Therapeutics for $9.2B to expand into long-acting antivirals. Find out what makes CD388 a potential flu game-changer.
Johnson & Johnson grabs RIPTAC cancer tech in $3bn Halda Therapeutics deal
Johnson & Johnson acquires Halda Therapeutics for $3.05B, expanding its oncology portfolio with precision prostate cancer treatments. Find out what’s next.
Metastatic TNBC sees unexpected remission as Kazia Therapeutics’ Q4 update reveals pipeline momentum across cancer programs
Learn how Kazia Therapeutics’ rare iCR in metastatic TNBC is reshaping its breast cancer, immuno-oncology, and GBM pipeline strategy.
FDA authorizes breakthrough Epkinly regimen from AbbVie for relapsed or refractory follicular lymphoma
Discover how AbbVie’s newly approved Epkinly regimen with rituximab and lenalidomide is redefining treatment for relapsed or refractory follicular lymphoma.